Abstract
A substantial reduction in asthma exacerbations in both children and adults has been seen in many countries worldwide during the COVID-19 pandemic.1,2 The cause of this reduction is likely to be multifactorial, but at least partly due to population-level public health measures, such as physical distancing, masking, and hand washing, which reduce broad viral transmission.2 This improvement in asthma control poses an interesting clinical dilemma: should clinicians consider tapering asthma medications in children during the pandemic in the face of good asthma control? Furthermore, if medicines are reduced during the COVID-19 pandemic, should clinicians return to the pre-COVID-19 schedule as respiratory precautions are gradually relaxed?
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
